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changes in MRL on payer’s and patient’s one year budget on the
example of angiotensin II blockers. METHODS: The three
models were build to assess the changes in payer’s and patient’s
budget/per patient if therapy is conducted using: 1) the only
original medications;2) only generic medications; or 3) if therapy
had been started with original medications and changed to the
generic (after changes on the list). All costs in polish zloty (zł): 1
euro ~ 3.80 zl. RESULTS: In all models (from 1 to 3) the payer’s
payment will decrease from 281 zł to 154 zł pe patient. From the
patient’s perspective the one year payment will rise from 767 zł
to 1048 zł or from 449 zł to 577 zł—depends on medication (in
model 1) and from 281 zł to 409 zł (in model 2), only in model
3 it will decrease from 767 zł to 409 zł. CONCLUSION: The
changes in MRL may lead to reduction of payer’s expenditures
and usually increase the patient’s expenditures. As a result it
could leads to reduction in patient’s access to medications.
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OBJECTIVES:Our aimwas to assess the social insurance costs of
hospital treatments for acute stroke inHungary between 2003 and
2005.We studied howmuch burden stroke patients impose on the
ﬁnancer (National Health Insurer Fund Administration) in acute
and chronic hospital admissions. METHODS: We extracted the
data of ‘new’ stroke patients (ICD-10: I60–64 diagnosis) hospi-
talized in May 2003 from the database of the ﬁnancer. We
analyzed active and chronic hospital treatment costs of these
patients in the period of 12 months before the stroke and in the
following ﬁrst and second 12 months. Data were distributed by
sex and age (age groups: 25–44, 45–64, over 65). We studied
patients hospitalized in May 2003 with the ICD-10: I60–64 main
diagnosis but not treated with the same diagnosis in the previous
24 months.RESULTS: In the ﬁrst 12 months of the active care the
burden of the disease was (male vs. female) 65+: 1018.4 vs. 823.2;
45–64: 1365.6 vs. 1122.0; 25–44: 1480.4 vs. 1224.4 Euro per
patient. In the second 12 months the costs were 202.4 vs. 144.8;
96.8 vs. 130.4; 110.4 vs. 99.2 Euro respectively.CONCLUSION:
Annual stroke costs of the Insurance Fund—based on our inci-
dence data (3535 patients/month)—amounted to 37.6 million
Euros in active and to 4.3 million Euros in chronic hospital care in
the ﬁrst 12 months, which is 1.68% of the total budget. Average
costs of stroke are higher in the case of males as are in the case of
females, 1459.2 vs. 1212.0 Euro in the ﬁrst 24 months. The
signiﬁcant difference results from active hospital treatment costs
(1326.0 vs. 1048.4 Euro), while the discrepancy is smaller in the
chronic hospital care (133.2 vs. 163.6 Euro).
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OBJECTIVES: Estimate the budget impact and the level of thera-
peutic goal attainment among patients with high cardiovascular
risk (HCR) in a population attending primary care setting (PCS)
and Hospital centres (HC) in a Spanish area. METHODS: Obser-
vational multicentre longitudinal study. Patients >55 years old
from seven PCC and two HC were recruited during 2006.
Deﬁnition of HCR as per modiﬁed NCEP-ATP III criteria.
The control cohort: patients without HCR. Main measures:
cardiovascular/general comorbidities, Charlson score (severity
[iCh]), clinical parameters (DP, SP, glucose, cholesterol, HCLc,
LDLc) and total costs variable/semi ﬁxed (visits, tests, drugs,
admissions, derivations, emergencies etc). A logistic regression
and covariance model was developed (ANCOVA-Bonferroni) to
correct the models (comorbidities-cost). SPSS program was used.
Level of signiﬁcance was p < 0.05. RESULTS: In all, 24,410
patient were studied, 15.4% (n = 2.766; IC:14,9–15,9%;
p = 0,000) had HCR, mean age: 68,2  9,5 years, women:
55,2%. HCR was associated with: men (OR = 2,7; IC:2,5–3,0),
dyslipidemia (OR = 1,5; IC:1,4–1,6), hypertension (OR = 1,2;
IC:1,1–1,3), diabetes (OR = 1,1; IC:1,0–1,2) and iCh (OR = 2,1;
IC:1,9–2,2), p < 0,0001. Differences for the group with and
without HCR were: Metabolic control: DP: 77,5  9,5 vs.
74,8  9,7; glucose: 104,0  29,4 vs. 111,3  36,5; Total cho-
lesterol: 211,6  38,7 vs. 192,4  41,5; LDL-cholesterol:
128,7  35,4 vs. 112,5  36,0; p = 0,000. HCR was related to
poly-pharmacy (62,5% vs. 26,1%) and average number of drugs
(6,4  3,5 for the HCR group vs. 4,0  2,9), p < 0,001. Drugs
accounted for 43.4% of total costs. Unitary adjusted cost per
year was 2.445.98€ (IC:2.382,07–2.509,90) for the HCR group
vs. 1.537,33€ (IC:1.505,53–1.569,13), p < 0.001. All compo-
nents of costs showed signiﬁcant differences between groups.
CONCLUSION: Patients with HCR had higher rates of
co-morbidity. Achievement of therapeutic objectives should
improve in patients without hypertension and total cholesterol
but with HCR (glucose, cLDL). Patients with this proﬁle use
more resources (particularly more drugs) and have higher health
care costs. Health professionals should develop common strate-
gies oriented to control main cardiovascular risk factors in
primary care.
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OBJECTIVES: Surgical techniques and immunosuppressive
drugs have been improved over the past decades, while the
method of preserving and transporting organs has not. In the UK
only 22.3% of hearts from all consented heart beating donors
were recovered in June 2005, whilst cold ischeamic time (CIT)
increased by an average of 34 minutes over 8 years. The Organ
Care System (OCS) may alleviate the organ shortage and
improve transplant outcomes by maintaining explanted hearts in
the normal functioning state ex-vivo. A health economic evalu-
ation analysis was undertaken to compute the economic beneﬁt
of improved transportability of explanted hearts from the UK
societal point of view. METHODS: Improved preservation with
OCS plus heart transplantation (IPTx) was compared to medical
management on the transplantation waiting list (MM) and heart
transplantation with conventional cold preservation method
(CPTx). We assumed that IPTx increases heart transplantation
rates by 40% and reduces CIT to <1 hr. UK cost vectors were
derived from the published literature. Twenty year direct medical
costs and QALYs were calculated for each arm. Reducing CIT to
<1 hr may extend the graft half life by 2.2 years (Schnitzler
2006). Discount rates of 6% were used for costs and 1.5% for
QALYs. WTP for a QALY gain was assumed to be 30,000 British
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Pounds (GBP). Cost of improved preservation technique was not
included in the model. RESULTS: IPTx may generate 4.18 and
1.19 QALY gain vs MM and CPTx respectively by increasing
heart transplantation rates and reducing the impact of CIT.
Treatment costs are reduced by 4476 GBP vs MM and increased
by 5768 GBP vs CPTx. CONCLUSION: Many patients die
on the waiting list due to the lack of transportability of hearts
from eligible donors. Improved preservation of explanted hearts
may generate 58′496 GBP of economic value per each heart
transplantation.
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OBJECTIVES: To assess the effects of various lipid-modifying
strategies on direct medical costs of coronary heart disease
(CHD) events among a representative patient cohort with estab-
lished CHD. METHODS: Model-based analysis, using data from
clinical trials, published literature, and national databases to
project CHD medical costs (emergency, inpatient, and outpa-
tient) over 5 years. The analysis focused on hypothetical cohorts
of 10,000 CHD patients (50 years of age or older) with any
abnormal lipid parameter (LDL-C, HDL-C, Non-HDL-C, and/or
TG). The expected number of CHD events was calculated using
the Framingham Heart Study equation for secondary prevention.
Age, sex, and coronary risk-factor data for patients with CHD
were obtained from a nationally-representative US health survey.
Direct medical costs were expressed in $US 2006, discounted
annually at 3%. The drugs of interest included simvastatin (S)
alone and ﬁxed-dose extended release niacin/simvastatin (ERN/
S), allowing an evaluation of increasing doses of S or adding a
second agent to S. RESULTS: Direct medical costs of CHD events
over 5 years are estimated to be approximately $3436 per patient
for patients treated with 20 mg of S. These costs would decrease
by 8.8% with 1000/20 mg of ERN/S. Compared to more aggres-
sive lipid therapy with 40 mg of S, 1000/40 mg of ERN/S would
decrease CHD costs by 9.1%. Relative to a maximum dose of
80 mg of S, the maximum dose of ERN/S (2000/40 mg) would
reduce CHD event costs by 11.2%. CONCLUSION: Intensifying
lipid-modifying therapy with ﬁxed-dose ERN/S combinations
would further reduce direct medical costs of CHD events more
effectively than S monotherapy in a secondary prevention popu-
lation. Further research on the cost-effectiveness of intensifying
dyslipidemia treatment is warranted.
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OBJECTIVES: Examine gender differences in resource use,
expenditures and mortality among U.S. Medicare patients fol-
lowing discharge from a hospital admission for congestive heart
failure (CHF). METHODS: Analyses were conducted on
national 5% sample of Medicare claims from January 1999 to
December 2001. A cohort that had an initial hospitalization with
a primary diagnosis of CHF was identiﬁed. Resource use at one
year preceding and following the initial CHF admission was
compared among males and females. Separate multivariate
regression models were developed by gender to assess the factors
associated with outcomes. Models included variables for patient
characteristics, comorbidity, compliance with routine care and
resource use in the year prior to CHF admission. RESULTS: A
majority of the 34,540 CHF patients were white (86%), one-half
were 80 years or older and approximately 58% were female.
Male CHF patients had a higher Charlson comorbidity score
compared to females (4.27 vs. 3.99; p < 0.0001). Females were
more likely than males to have an inpatient readmission within
365 days (58.6% vs. 41.2%; p = 0.016), an emergency depart-
ment visit within 180 days preceding (58.3% vs. 41.7%;
p = 0.0019) and following CHF admission (57.7% vs. 42.3%;
p = 0.035), physician ofﬁce visits within 365 days preceding
(58.5% vs. 41.5%; p = 0.0001) and following CHF admission
(57.7% vs. 42.3%; p = 0.0001). Females were also more likely
than males to die within 60 days (56.3% vs. 43.7%; p = 0.009),
90 days (56.5% vs. 43.5%; p = 0.006), 180 days (56.2%
vs. 43.8%; p = 0.0001) and 365 days (56.1% vs. 43.9%;
p < 0.0001) of the initial CHF admission. In multivariate models,
factors associated with health care resource use, expenditures
and mortality had similar trends in both gender models. CON-
CLUSION: There appears to be gender differences in resource
use and outcomes among CHF patients. Effort to better target
interventions, diagnostic and therapeutic, among patients
at higher risk of adverse outcomes carries potential for cost-
effective management of CHF patients.
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OBJECTIVES: Determine hypertension-related costs and cost-
effectiveness ratios of pharmaceutical treatment for patients with
hypertension in Greece METHODS: Data was derived from the
PharmacoECOnomic Assessment of Prognostic Risk Occupa-
tional Survey (ECON-APROS), a cross-country prospective
study. The sample included individuals 30–75 yrs old, diagnosed
with hypertension (Systolic Blood Pressure >140 mmHg and/or
Diastolic Blood Pressure >90 mmHg), who were treated and
monitored for a period of 1 year after the diagnosis. Patients
were separated in two subgroups: a) those with uncomplicated
hypertension (N = 1243) and b) those with complications e.g.
CVD, CHD, MI etc. (N = 122). Demographic, clinical and socio-
economic information was collected. Cost analysis was based on
the direct cost estimations and the measurement of the effective-
ness was based on the absolute reductions in the mean SBP for
each subgroup after 1 year of treatment. The perspective of the
Greek NHS was taken. Tariffs are referred to 2006 prices and
costs are expressed in Euros. RESULTS: Mean direct cost per
patient suffering from uncomplicated hypertension was esti-
mated at 687€ per year while for the second subgroup was
signiﬁcantly higher at 1771€ per year. Mean reduction in the
patients’ Systolic Blood Pressure was 32.58 mmHg for the ﬁrst
subgroup and 34.38 mmHg for the second. Cost-effectiveness
ratios for each subgroup were estimated at 21.1€/mmHg and
51.7€/mmHg, respectively, for every 1 mmHg lowering of the
Systolic Blood Pressure. CONCLUSION: The long term conse-
quences of untreated hypertension are both life-threatening, for
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